搜尋結果
5 天前 · damage repair gene germline profiling for metastatic prostate cancer patients of different ancestries. Prostate 82:1196-1201, 2022 Crossref PubMed Google Scholar 5. VanderWeele DJ, Finney R, Katayama K, et al: Genomic heterogeneity within 5:416 ...
2 天前 · Assess trends in the epidemiology of prostate cancer and prostate cancer mortality. Analyze whether men with metastatic prostate cancer are more likely to die from other causes. Outline implications for the healthcare team.
- Deputy News Editor Medscape Medical News
5 天前 · Prostate cancer image. Testosterone fuels the growth of prostate cancer. The target of testosterone is the androgen receptor. Metastatic prostate cancer is treated by reducing levels of testosterone, and despite initial responses to treatment, nearly all patients become resistant to androgen deprivation therapy.
1 天前 · Metastatic Castration-Resistant Prostate Cancer: New Targets, New Therapeutic Approaches. The landscape of mCRPC treatment has greatly changed in the past 2 years. An expert panel discusses recent progress and ongoing challenges. Authors: Christopher J. Logothetis, MD; Tomasz M. Beer, MD; Johann Sebastian de Bono, MB, ChB, MSc, PhD; Fred Saad, MD.
3 天前 · Background The proposed trial is to examine the feasibility of prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT)-guided cytoreduction plus apalutamide and androgen deprivation therapy (ADT) for newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) at oligometastatic state. Methods CHAMPION (NCT05717582) is an open-label, single ...
5 天前 · Metastatic castration-resistant prostate cancer (mCRPC) patients with symptomatic skeletal metastases can be treated with radium-223 therapy. This alpha emitter that selectively targets bone metastases was proven to be of clinical benefit in the phase 3 ALSYMPCA trial. 1
3 天前 · In this module, I will discuss novel molecular targets for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic castration-resistant prostate cancer (mCRPC) and unique pathways that lead to mCRPC and mHSPC progression.
